Get my own profile
Public access
View all4 articles
1 article
available
not available
Based on funding mandates
Co-authors
- Noreen F. RizviMerck Research LabsVerified email at merck.com
- Alan NorthrupMerck & Co., IncVerified email at merck.com
- Julja BurchardSenior Director, Bioinformatics, Sera PrognosticsVerified email at seraprognostics.com
- Andreas BenderProfessor for Molecular Informatics in CambridgeVerified email at cam.ac.uk
- Charles LesburgOdyssey TherapeuticsVerified email at odysseytx.com
- Solomon KattarMerckVerified email at merck.com
- Ali NahviHead of Platform Research, Flagship Labs 85, Inc.Verified email at fl85inc.com
- Daniel J KleinComputational & Structural Chemistry, Merck & Co., Inc.Verified email at merck.com
- Rodrigo AguilarAssistant Professor, Institute for Biomedical Sciences, Universidad Andres BelloVerified email at uandresbello.edu
- Corey StricklandProteovantVerified email at coreyandpam.net
- Scott EdmondsonNimbus TherapeuticsVerified email at nimbustx.com
- Peter Seth KutchukianNovartis Institutes for BioMedical Research (NIBR)Verified email at novartis.com
- Joel A. KlappenbachExecutive Director, Emerging Science & Innovation, OncologyVerified email at pfizer.com
- John P. Santa Maria Jr.Fog Pharmaceuticals IncVerified email at fogpharma.com
- J R EverettUniversity of GreenwichVerified email at greenwich.ac.uk
- Hongbin YangUniversity of CambridgeVerified email at cam.ac.uk
- Debbie FlusbergVerified email at post.harvard.edu
- Dean G. BrownJnana TherapeuticsVerified email at jnanatx.com
- Heike Julia WobstJnana TherapeuticsVerified email at jnanatx.com
- Charles MowbrayDiscovery DirectorVerified email at dndi.org
Follow
Graham Frank Smith
AstraZeneca, Merck, Pfizer, Rhone-Poulenc Rorer, Ohio State, Nottingham University
Verified email at astrazeneca.com